Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 17Sarcoma 6Gastrointestinal 5Genitourinary 4Dermatologic 4Thoracic 3Head & Neck 3Breast 3Lymphoid 2CNS 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Glioblastoma 28Glioma 20Brain Neoplasms 18Astrocytoma 13Neuroblastoma 12Lung Neoplasms 11Breast Neoplasms 10Medulloblastoma 9Central Nervous System Neoplasms 9Osteosarcoma 7Carcinoma, Non-Small-Cell Lung 7Wilms Tumor 6Lymphoma, Non-Hodgkin 6Hepatoblastoma 6Ependymoma 6Rhabdoid Tumor 5Neuroectodermal Tumors, Primitive, Peripheral 5Meningioma 5Meningeal Carcinomatosis 5Melanoma 5Histiocytosis, Langerhans-Cell 5Gliosarcoma 5Sarcoma 4Rhabdomyosarcoma 4Prostatic Neoplasms 4Pheochromocytoma 4Paraganglioma 4Neoplasm Metastasis 4Ganglioneuroblastoma 4Thyroid Neoplasms 3

Interventions

X-Rays 2Trastuzumab 2Specimen Handling 2Nivolumab 2Irinotecan 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sargramostim 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1montelukast 1larotrectinib 1ipatasertib 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Specimen Handling × CNS × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡